[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation-treatment":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100658853","phase-1-using-silverlon-for-head-and-neck-patients-with-tracheostomies-100658853",false,"NCT07856732","Using Silverlon® for Head and Neck Patients With Tracheostomies","Feasibility and Tolerability of Silverlon® for Definitive Head and Neck Patients With Tracheostomies","Inclusion Criteria:\n\n* Undergoing definitive head and neck cancer (\\>4 weeks of treatment)\n* Have a tracheostomy\n* Age ≥ 18 years\n* Must be able to understand and write English\n\nExclusion Criteria:\n\n* Inability to fulfill requirements of the protocol\n* Presence of unhealed surgical wounds\n* Subjects unable or unwilling to wear Silverlon dressings\n* Active infection of treatment area\n* Any co-morbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol.\n* Subjects with known sensitivity to silver or nylon.","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purpose of this study is to determine if prophylactic silver-nylon burn dressing Silverlon® prevents a severe skin reaction under tracheostomy collars. It also aims to establish whether patients can tolerate Silverlon® under their tracheostomy with daily removal and weekly changes.",[26,27,28],"Head and Neck Cancer","Radiation Dermatitis Acute","Radiation Treatment","RECRUITING","2026-09-30",{"date":32,"type":33},"2026-10-05","ACTUAL",{"date":35,"type":33},"2026-08-30",{"date":37,"type":20},"2028-01-30",{"name":39,"class":40},"State University of New York - Upstate Medical University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100524645","long-term-neurovascular-complications-after-radiation-therapy-in-head-and-neck-cancer-100524645","NCT06111430","Long-term Neurovascular Complications After Radiation Therapy in Head and Neck Cancer","The Ambidirectional Cohort Study of Neurovascular Complications After Radiation Therapy in Head and Neck Cancer Patients","Population: Prospective cohort\n\nInclusion Criteria:\n\n1. Age ≥20 years.\n2. Head and neck cancer patient .\n3. Had ever received radiation therapy (RT) ≦ 72 months before inclusion in the registry.\n4. Had ≥ 1 brain images and cervical-cranial vascular studies between the end of RT and d date of enrolment.\n\nExclusion Criteria:\n\n1. Age \\\u003C20 years.\n2. Patients not willing to sign the informed consent.\n\nPopulation: Retrospective validation cohort\n\nInclusion Criteria:\n\n1. Age ≥20 years.\n2. Head and neck cancer patient.\n3. Had ever received radiation therapy (RT) \\> 120 months before the adoption date of IRB at the participant site.\n4. Had ≥ 2 brain images and cervical-cranial vascular studies between the end of RT and 6\\~10 years after RT, one within 5 years after RT, the other after 5 years after RT.\n\nExclusion Criteria:\n\n1.Age \\\u003C20 years.","20 Years","100 Years",{"count":52,"type":20},800,"OBSERVATIONAL","Head and neck cancer is a group of cancers develop from the soft tissues, salivary gland, mucosa of the upper respiratory or digestive system covering the oral and nasal cavity. Radiotherapy is usually the standard treatment of Head and neck cancers. In the present study, investigators aim to study the prevalence of cervical-cranial vascular complications during the early stages in these Head and neck cancer patients receiving Radiotherapy. Investigators will also compare the results between Nasopharyngeal cancer and other Head and neck cancerpatients receiving Radiotherapy.",[28,56],"Neurovascular Complications","2026-03-18",{"date":59,"type":33},"2026-03-20",{"date":61,"type":33},"2022-04-11",{"date":63,"type":20},"2026-04-10",{"name":65,"class":40},"Chang Gung Memorial Hospital",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":41},"100557329","trial-comparing-avg-global-qual-of-lifescore-in-hypo-frac-rt-vs-conv-frac-in-hn-cancers-100557329","NCT06536699","Trial Comparing Avg. Global Qual of Lifescore in Hypo Frac. RT vs Conv. Frac. in H&N Cancers","A Randomised Non Inferiority Trial to Compare the Average Global Quality of Life Score Following Hypofractionated Radiotherapy Versus Conventional Fractionation in Head and Neck Cancers","HYPORT-HN","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. ECOG performance status 0 - 2.\n3. Patients diagnosed with invasive squamous cell cancer of the head and neck region which includes lip, oral cavity, nasopharynx, oropharynx, hypopharynx, supraglottis, glottis and subglottis.\n4. Patients who are being treated with curative intent treatment either with surgery followed by adjuvant radiotherapy with or without chemotherapy or definitive chemoradiation.\n5. Patients must have a histopathological proof of malignancy, such as biopsy or post operative histopathology report. Biopsies or surgeries done outside must have been reviewed for pathological confirmation and specimen adequacy at the treating institute.\n6. Patients with non metastatic cancer, optimally staged with the following:\n\n   1. Contrast enhanced CT scan of the neck and thorax for cancer lip, oral cavity, oropharynx, hypopharynx, supraglottis, glottis and subglottis\n   2. Magnetic Resonance Imaging of the neck and CT thorax for cancer of nasopharynx\n\nExclusion Criteria:\n\n1. Concurrent illness like severe cardiac, renal or hepatic dysfunction and, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety\n2. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol.","80 Years",{"count":76,"type":20},600,[78],"NA","Radiotherapy forms an integral part of Head and Neck cancer treatment in both definitive as well as adjuvant setting. This study explores the use of hypofractionated radiotherapy, delivering 55Gy in 20 fractions over 4 weeks in comparison to the conventional approach which involves 70 Gy over 6 weeks.\n\nHypofractionated radiotherapy would result in significant benefits in terms of shortening the overall treatment time, countering accelerated hypofraction effects that typically arise after the 4th week. The new approach is also anticipated to offer resource and financial advantages, involving less machine time per patient, and potentially leading to better patient compliance. Previous studies on hypofractionation in Head and Neck cancer have demonstrated good local control and acceptable toxicity levels compared to conventional methods.\n\nThe primary objective of this study is to compare the average global quality of life following hypofractionated radiotherapy versus conventional fractionation, with secondary objectives including a comparison of locoregional control at 2 years and assessment of acute and late toxicities.\n\nThe study will require 600 eligible patients randomly assigned to either the hypofractionated or conventional arm. For definitive chemoradiation, the control arm will receive 66Gy in 30 fractions over 6 weeks, while the experimental arm will receive 55Gy in 20 fractions over 4 weeks, along with Inj Cisplatin @ 100mg\u002Fm2 3 weekly for 2 cycles. In the adjuvant setting control arm will receive 60Gy in 30 fractions over 6 weeks and experimental arm will receive 52.5Gy in 20 fractions over 4 weeks along with Inj Cisplatin @ 100mg \u002Fm2 3 weekly for 2 cycles for both arms based on histopathological indications.\n\nPhysician reported and patient reported acute toxicities like mucositis, dermatitis and dysphagia, weight loss, requirement and duration of feeding tubes as well as patients reported outcomes in the form of EORTC QLQ C30, HN43 and XeQoLS will be recorded both during and after treatment at regular intervals for 2 years.\n\nThe study's duration is five years, aiming to determine whether the hypofractionated schedule is non-inferior to conventional radiotherapy in terms of safety and disease-related outcomes",[28],[82,83],"Hypofractionated radiotherapy","Head and Neck cancer","NOT_YET_RECRUITING","2024-08-02",{"date":87,"type":33},"2024-08-05",{"date":89,"type":20},"2024-08-07",{"date":91,"type":20},"2031-07-01",{"name":93,"class":40},"Tata Medical Center"]